Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic lymphocytic leukemia
Pharma
Bristol Myers bags FDA nod to bring CAR-T to CLL
BMS' Breyanzi, a one-time CAR-T therapy, will compete with Eli Lilly's Jaypirca, a chronic oral drug, in CLL following BTK and BCL-2 inhibitors.
Angus Liu
Mar 15, 2024 9:46am
Lilly’s Jaypirca tipped to capture 60% of BTK leukemia market
Jan 22, 2024 11:59am
Lilly's Jaypirca blazes CLL trail with FDA approval
Dec 4, 2023 4:11am
AbbVie's Imbruvica-Brukinsa patent suit may have merit: expert
Jun 27, 2023 10:48am
AbbVie sues BeiGene over brand-new Imbruvica patent
Jun 15, 2023 10:35am
ASCO: BMS pitches Breyanzi as the first CAR-T for CLL
May 25, 2023 5:00pm